TY - JOUR AU - Tenover, Fred AU - Kalsi, Rajinder AU - Williams, Portia AU - Carey, Roberta AU - Stocker, Sheila AU - Lonsway, David AU - Rasheed, J. Kamile AU - Biddle, James AU - McGowan, John AU - Hanna, Bruce T1 - Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing T2 - Emerging Infectious Disease journal PY - 2006 VL - 12 IS - 8 SP - 1209 SN - 1080-6059 AB - Detecting β-lactamase–mediated carbapenem resistance among Klebsiella pneumoniae isolates and other Enterobacteriaceae is an emerging problem. In this study, 15 blaKPC-positive Klebsiella pneumoniae that showed discrepant results for imipenem and meropenem from 4 New York City hospitals were characterized by isoelectric focusing; broth microdilution (BMD); disk diffusion (DD); and MicroScan, Phoenix, Sensititre, VITEK, and VITEK 2 automated systems. All 15 isolates were either intermediate or resistant to imipenem and meropenem by BMD; 1 was susceptible to imipenem by DD. MicroScan and Phoenix reported 1 (6.7%) and 2 (13.3%) isolates, respectively, as imipenem susceptible. VITEK and VITEK 2 reported 10 (67%) and 5 (33%) isolates, respectively, as imipenem susceptible. By Sensititre, 13 (87%) isolates were susceptible to imipenem, and 12 (80%) were susceptible to meropenem. The VITEK 2 Advanced Expert System changed 2 imipenem MIC results from >16 μg/mL to <2 μg/mL but kept the interpretation as resistant. The recognition of carbapenem-resistant K. pneumoniae continues to challenge automated susceptibility systems. KW - carbapenem KW - imipenem KW - meropenem KW - susceptibility testing KW - Klebsiella KW - beta-lactamase KW - carbapenemase KW - research KW - United States DO - 10.3201/eid1208.060291 UR - https://wwwnc.cdc.gov/eid/article/12/8/06-0291_article ER - End of Reference